Acute Management of Supraventricular Tachycardia

Hemodynamically Unstable Presentations

Immediate synchronized cardioversion is indicated for patients presenting with hypotension, altered mental status, shock, chest pain, or acute heart‑failure symptoms 1.
In regular, narrow‑complex SVT, a brief trial of adenosine may be considered before cardioversion 1.
Synchronized cardioversion is highly effective for terminating SVT and should be employed early to avoid complications from anti‑arrhythmic drugs [2][3].
Defibrillation equipment must be readily available whenever adenosine is administered because the drug can precipitate atrial fibrillation with rapid ventricular response or even ventricular fibrillation [2][3].

First‑Line Therapy for Stable Patients – Vagal Maneuvers

Perform vagal maneuvers with the patient supine as the initial intervention [2][4].
Valsalva maneuver – have the patient bear down against a closed glottis for 10–30 seconds, generating ≥30–40 mm Hg intrathoracic pressure [4][5].
Carotid sinus massage – after confirming the absence of a carotid bruit, apply steady pressure over either carotid sinus for 5–10 seconds [4][5].
Ice‑cold facial towel – apply a wet, ice‑cold towel to the face to exploit the diving reflex [4][5].
Alternating Valsalva and carotid massage yields an overall success rate of ≈27.7 % [2][4].
Applying pressure to the eyeball is prohibited because it is potentially dangerous [2][4].

Second‑Line Therapy – Adenosine

Administer adenosine if vagal maneuvers fail [2][4]6.
Adenosine terminates AV‑node re‑entrant tachycardia in ~95 % of cases and orthodromic AV‑reciprocal tachycardia in 90–95 % of cases [4][5].
Minor, brief (<1 minute) side effects occur in ~30 % of patients [2][3].
Adenosine may precipitate atrial fibrillation that conducts rapidly to the ventricles, with a theoretical risk of ventricular fibrillation [2][3].

Third‑Line – Intravenous Calcium‑Channel Blockers

Intravenous diltiazem or verapamil terminate SVT in 64–98 % of patients 1.
These agents are more effective than beta‑blockers for acute termination [4][5].
Administer slowly over up to 20 minutes to minimize hypotension 1.
Do not use calcium‑channel blockers if ventricular tachycardia or pre‑excited atrial fibrillation is suspected, and avoid them in patients with systolic heart failure [1][4].

Third‑Line – Intravenous Beta‑Blockers

Intravenous beta‑blockers are a reasonable alternative with an excellent safety profile [1][4].
They are less effective than diltiazem in head‑to‑head comparisons [4][5].

Fourth‑Line – Synchronized Cardioversion

Proceed to synchronized cardioversion when pharmacologic therapy is ineffective or contraindicated [2][3].
Because pharmacologic agents succeed in 80–98 % of cases, cardioversion is required only rarely [2][3]1.
Perform cardioversion after adequate sedation or anesthesia in hemodynamically stable patients [2][3].
Consider a second drug bolus or a higher dose before resorting to cardioversion [3][4].

Pre‑Excited Atrial Fibrillation (Wide‑Complex Irregular Tachycardia)

If the patient is unstable, immediate synchronized cardioversion is required [2][3]; rapid pre‑excited AV conduction can precipitate ventricular fibrillation [2][3].
In stable patients, ibutilide or intravenous procainamide should be used because they slow conduction over the accessory pathway and may terminate atrial fibrillation [2][3].
Never use AV‑nodal blockers (diltiazem, verapamil, beta‑blockers) in pre‑excited atrial fibrillation, as they can enhance accessory‑pathway conduction and accelerate the ventricular rate [3][7].

Focal Atrial Tachycardia

Intravenous beta‑blockers, diltiazem, or verapamil terminate or slow the ventricular rate in ≈30–50 % of patients 8.
Close monitoring for hypotension or bradycardia is required 8.

Ongoing Management of Recurrent SVT

For patients who decline catheter ablation, oral beta‑blockers, diltiazem, or verapamil provide effective long‑term control in the absence of ventricular pre‑excitation [1][6].
Catheter ablation should be offered as the first‑line definitive treatment because of its high success rate and low complication profile 9.

Critical Pitfalls to Avoid

Do not use AV‑nodal blockers in wide‑complex tachycardia until ventricular tachycardia and pre‑excited atrial fibrillation are definitively excluded [1][4].
Avoid calcium‑channel blockers in patients with systolic heart failure [1][4].
Digoxin, amiodarone, and sotalol are no longer recommended for acute SVT management 9.
Ensure cardioversion equipment is immediately available when administering adenosine [2][3].
Confirm the absence of a carotid bruit before performing carotid sinus massage [4][5].

Management of Supraventricular Tachycardia in End‑Stage Renal Disease

Assessment & Immediate Stabilization

In patients with end‑stage renal disease (ESRD) presenting with supraventricular tachycardia (SVT), promptly assess hemodynamic status and correct potassium, magnesium, and calcium abnormalities before initiating standard SVT protocols, because electrolyte shifts during and after dialysis are the primary trigger for arrhythmias in this population. 10, 11
Check serum potassium, magnesium, and calcium levels immediately on presentation; fluctuations in these electrolytes are the main arrhythmogenic trigger in ESRD patients. 10, 11
Monitor electrolyte concentrations continuously throughout hemodialysis and for the subsequent 4–5 hours, the period when SVT episodes most frequently occur. 10, 11
Correct any identified electrolyte imbalances before or concurrently with anti‑arrhythmic drug administration. 10, 11
Hemodynamically unstable patients (e.g., hypotension, altered mental status, shock, chest pain, acute heart failure) should receive immediate synchronized cardioversion. 12, 13
Hemodynamically stable patients should follow a stepwise pharmacologic algorithm. 12, 13

Acute Pharmacologic Management (Stable Patients)

First‑Line Vagal Maneuvers

A modified Valsalva maneuver performed supine, followed by passive leg raise and supine repositioning, raises conversion success to approximately 50 %. 12

Second‑Line Adenosine

Adenosine is the drug of choice after failed vagal maneuvers, achieving 91–95 % termination of AV‑node re‑entrant tachycardia (AVNRT) and atrioventricular re‑entrant tachycardia (AVRT). 12, 13
Adenosine is contraindicated in patients with asthma because of the risk of severe bronchospasm. 12

Third‑Line Calcium‑Channel Blockers

Intravenous diltiazem or verapamil terminate SVT in 64–98 % of cases. 12
Both agents require dose adjustment for renal impairment; they should be administered slowly (up to 20 min) and patients monitored closely for hypotension. 14

Third‑Line Beta‑Blockers

Intravenous metoprolol or esmolol are reasonable alternatives with an excellent safety profile. 12, 15
In ESRD, renally cleared β‑blockers such as atenolol and sotalol need substantial dose reduction; hepatic‑metabolized agents (metoprolol, carvedilol) are preferred. 14

Fourth‑Line Synchronized Cardioversion

If pharmacologic therapy fails or is contraindicated, proceed to synchronized cardioversion, which is required in only 2–20 % of cases given the high success of drug therapy. 13

Timing Relative to Dialysis

SVT episodes cluster during hemodialysis and for the next 4–5 hours because of rapid electrolyte and volume shifts. 10, 11
In hemodynamically stable patients, elective cardioversion may be postponed until post‑dialysis electrolyte levels have stabilized. 10, 11

Drug Selection Pitfalls in ESRD

Avoid sotalol entirely in ESRD patients; it is renally cleared and has been linked to long‑QT syndrome in this population. 10, 11
Digoxin and amiodarone are no longer recommended for acute SVT management in ESRD. 16
Restricted vascular access can limit the choice and delivery of IV therapies; central‑line access permits the use of lower adenosine doses (as low as 1 mg). 10, 11, 12

Long‑Term Management

Catheter Ablation

Offer catheter ablation as the first‑line definitive therapy for recurrent symptomatic SVT; success rates range from 94.3 % to 98.5 %, with very low complication rates, making it preferable to chronic anti‑arrhythmic drugs in ESRD patients, especially those awaiting renal transplantation and expected to survive >1 year. 10, 11

Chronic Pharmacologic Therapy (when ablation is declined)

Maintain rhythm control with oral β‑blockers (metoprolol, carvedilol) or calcium‑channel blockers (diltiazem, verapamil); prioritize agents cleared hepatically over renally cleared alternatives. 15, 14
Regularly monitor therapeutic response and adjust doses based on clinical effect and side‑effects. 14

Critical Pitfalls to Avoid

Never use AV‑nodal blocking agents in wide‑complex tachycardia until ventricular tachycardia and pre‑excited atrial fibrillation have been excluded. (supported by clinical consensus)
Do not overlook electrolyte correction; it remains the most important intervention specific to ESRD SVT management. 10, 11
Avoid calcium‑channel blockers in patients with systolic heart failure, a common comorbidity in ESRD. (clinical guideline)

Guideline Summary for Supraventricular Tachycardia (SVT) Management

Causes and Pathophysiology

Supraventricular tachycardia is primarily caused by re‑entry mechanisms involving the atrioventricular (AV) node or accessory pathways; AV‑node re‑entry tachycardia (AVNRT) and AV‑re‑entry tachycardia (AVRT) are the most common forms【17】.
AVNRT arises from dual AV‑node physiology, where two pathways with different conduction properties form a re‑entry circuit【17】.
AVRT (Wolff‑Parkinson‑White syndrome) results from accessory pathways that directly connect atria and ventricles, creating an alternative re‑entry circuit【17】.
Focal atrial tachycardia originates from discrete atrial ectopic foci that generate abnormal electrical activity【17】.
Common triggers include exercise, caffeine, tea, alcohol, or spontaneous onset【17】.

Acute Management – Hemodynamically Unstable Patients

Immediate synchronized cardioversion is the definitive treatment for unstable SVT (hypotension, altered mental status, shock, chest pain, acute heart failure) and restores sinus rhythm in essentially all patients【17】.

Acute Management – Hemodynamically Stable Patients

First‑Line: Vagal Maneuvers

Performing vagal maneuvers with the patient supine converts approximately 43 % of SVT episodes【17】.
Modified Valsalva: patient strains against a closed glottis for 10–30 seconds, generating intrathoracic pressure ≥30–40 mm Hg【17】.
Carotid sinus massage (after confirming absence of carotid bruit) applied for 5–10 seconds can terminate SVT【17】.
Immersion reflex (cold, wet towel applied to the face) is an additional vagal technique【17】.
Alternating Valsalva and carotid massage increases overall conversion success to about 27.7 %【17】.

Second‑Line: Adenosine

Adenosine is the drug of choice after failed vagal maneuvers, converting 90–95 % of AVNRT/AVRT episodes【17】.
Dosing protocol: 6 mg rapid IV bolus followed by a 20 mL saline flush; if no conversion within 1–2 min, a second 12 mg bolus is given【17】.
A defibrillator must be immediately available because adenosine can precipitate atrial fibrillation with rapid ventricular response or ventricular fibrillation【17】.
Transient side effects occur in ~30 % of patients and resolve within <1 minute【17】.
Dose adjustments: reduce initial dose to 3 mg in patients on dipyridamole, carbamazepine, or heart‑transplant recipients; increase dose when the patient is taking theophylline or caffeine【17】.
Adenosine is contraindicated in asthma due to risk of severe bronchospasm【17】.

Third‑Line: Intravenous Calcium‑Channel Blockers or β‑Blockers

Intravenous diltiazem or verapamil achieve conversion in 64–98 % of SVT cases and are preferred when β‑blockers are not tolerated or after adenosine failure【17】.
Infusion up to 20 minutes can mitigate hypotension risk【17】.
Contraindications: avoid calcium‑channel blockers if ventricular tachycardia or pre‑excited atrial fibrillation is suspected, and avoid in systolic heart‑failure patients【17】.
Intravenous β‑blockers are reasonable alternatives with an excellent safety profile, though slightly less effective than calcium‑channel blockers【17】.

Fourth‑Line: Synchronized Cardioversion

When pharmacologic therapy fails or is contraindicated in stable patients, synchronized cardioversion (after adequate sedation) succeeds in 80–98 % of cases【17】.
Consider a second drug bolus or a higher drug dose before proceeding to cardioversion【17】.

Special Situation – Pre‑Excited Atrial Fibrillation (Wolff‑Parkinson‑White)

Unstable pre‑excited atrial fibrillation requires immediate synchronized cardioversion because rapid AV conduction can precipitate ventricular fibrillation【17】.
In stable patients, intravenous ibutilide or procainamide should be used to slow conduction over the accessory pathway and terminate atrial fibrillation【17】.
AV‑node blocking agents (adenosine, diltiazem, verapamil, digoxin, β‑blockers) must never be used in pre‑excited atrial fibrillation, as they may accelerate ventricular response and precipitate ventricular fibrillation【17】.

Chronic and Long‑Term Management

Catheter Ablation (First‑Line Definitive Therapy)

Catheter ablation is recommended as first‑line definitive therapy for recurrent symptomatic SVT, with single‑procedure success rates of 94.3–98.5 %【17】.
The procedure has a very low complication profile and should be considered for all patients with recurrent SVT【17】.

Long‑Term Pharmacotherapy (When Ablation Is Not Performed)

Oral β‑blockers, diltiazem, or verapamil are effective for ongoing SVT control in patients who decline or are unsuitable for ablation【17】.
Patients should be monitored for bradyarrhythmias and hypotension after initiation; these agents should be avoided in systolic heart‑failure patients【17】.

Safety Precautions

Always have a defibrillator ready when administering adenosine due to the risk of precipitating dangerous atrial fibrillation【17】.
Avoid calcium‑channel blockers or β‑blockers if pre‑excited atrial fibrillation or ventricular tachycardia is suspected【17】.

Safety Considerations for Pre‑hospital Adenosine Cardioversion in Supraventricular Tachycardia (SVT)

Potential Adverse Cardiac Effects

Adenosine can precipitate life‑threatening arrhythmias such as atrial fibrillation with rapid ventricular response or ventricular fibrillation, which may require immediate defibrillation. American College of Cardiology/American Heart Association/Heart Rhythm Society (Circulation 2016) 18.

Post‑Conversion Arrhythmias

After successful conversion, patients frequently develop atrial or ventricular premature complexes that can trigger recurrent SVT and may necessitate anti‑arrhythmic medication. American College of Cardiology/American Heart Association/Heart Rhythm Society (Circulation 2016) 19.

Guideline Position on Pre‑hospital Treat‑and‑Release

The ACC/AHA/HRS guidelines do not address pre‑hospital “treat‑and‑release” after adenosine; all recommendations assume hospital‑based care with continuous monitoring. American College of Cardiology/American Heart Association/Heart Rhythm Society (Circulation 2016) [18][19]20.

Hemodynamic Stability Requirements

Patients must remain hemodynamically stable throughout the encounter (no hypotension, altered mental status, chest pain, or heart‑failure symptoms) to be considered for any treat‑and‑release protocol. American College of Cardiology/American Heart Association/Heart Rhythm Society (Circulation 2016) 20.

Immediate Transport Indications

Any occurrence of hemodynamic instability at any point (hypotension, altered mental status, chest pain, or heart‑failure symptoms) mandates transport to the emergency department. American College of Cardiology/American Heart Association/Heart Rhythm Society (Circulation 2016) 20.

Exclusion of High‑Risk Cardiac Substrates

Patients with high‑risk features—pre‑excitation syndromes (e.g., Wolff‑Parkinson‑White), structural heart disease, or recent myocardial infarction—should not be managed with a treat‑and‑release approach. American College of Cardiology/American Heart Association/Heart Rhythm Society (Circulation 2016) 18.

Rationale for Transport

Transport enables comprehensive evaluation to rule out underlying structural heart disease, pre‑excitation syndromes, and other conditions that increase the risk of adverse outcomes after adenosine. American College of Cardiology/American Heart Association/Heart Rhythm Society (Circulation 2016) [18][19].